Trial Profile
A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors FibroGen
- 11 Jul 2023 Interventional Study Model has been changed to Parallel, this study is now an Randomized trial, Primary endpoints has been added, hence trial focus has been shifted to PK, AR, PD.
- 05 Sep 2014 New trial record